Global (United States, European Union and China) Pain Management

Pain Management Comprehensive Study by Type (Pharmaceuticals, Devices), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain, Musculoskeletal Pain, Neuropathic Pain, Obstetrical Pain), Drug Class (NSAIDS, Anticonvulsants, Antidepressants, Anti-migraine agents, Non-narcotic analgesics, Opioids), Mode Of Purchase (Over-The-Counter, Prescription Based) Players and Region - Global Market Outlook to 2028

Pain Management Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pain Management
Pain management refers to the medical specialty or approach aimed at reducing and controlling pain experienced by individuals. It involves various techniques and strategies to alleviate pain and improve a person's quality of life. Pain can arise from various sources, such as injuries, medical conditions, surgeries, or chronic conditions. Pain management involves a multidisciplinary approach that may include medications, physical therapy, psychological interventions, etc.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The market is fragmented by both small and big players who have locked horns with each other in the market and are making tireless efforts to gain supremacy over their counterparts. This cut-throat competition is expected to prove beneficial for the consumers who will now have a wide range of vendors, each of whom is willing to go an extra mile to attract the consumers. The strategy that can help these players in growing their customer base and expansion of their product portfolio. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pain Management market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Novartis AG(Switzerland), Merck & Co. Inc. (United States), Boston Scientific Corporation (United States), Becton, Dickinson and Company (United States), Medtronic PLC (Ireland), Johnson & Johnson Services, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Abbott Laboratories (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Mallinckrodt Pharmaceuticals (United Kingdom), AstraZeneca PLC. (United Kingdom), Purdue Pharma L.P. (United States), Depomed, Inc. (United States) and Endo International Plc. (Ireland).

Segmentation Overview
AMA Research has segmented the market of Global Pain Management market by Type (Pharmaceuticals and Devices), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain, Musculoskeletal Pain, Neuropathic Pain and Obstetrical Pain) and Region.



On the basis of geography, the market of Pain Management has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Class, the sub-segment i.e. NSAIDS will boost the Pain Management market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Mode Of Purchase, the sub-segment i.e. Over-The-Counter will boost the Pain Management market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Popularity of Rechargeable Spinal Cord Stimulators and Development of New Pain Management Technology

Market Growth Drivers:
Increasing Demand for Long-Term Pain Management among the Geriatric Population and High Proven Effectiveness of Pain Management Devices for the Treatment of Chronic Pain

Challenges:
Availability of Alternative Therapies for Pain Management

Restraints:
Low Awareness about the Use of Pain Management and Dearth of Pain Specialists and Low Number of Pain Clinics in Several Countries

Opportunities:
High Growth in the Number of Patients Suffering From Neuropathic Pain and Strict Regulations to Limit Opioid Pain Killer Prescriptions

Market Leaders and their expansionary development strategies
On May 9, 2019 - Boston Scientific announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company that has developed and commercialized the Superion Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS).
In January 2021, Boston Scientific Corporation launched the WaveWriter Alpha, a portfolio of spinal cord stimulator (SCS) systems that combine therapy options for personalized pain relief.
In the United States, pain management falls under the purview of various regulatory bodies, including the Drug Enforcement Administration (DEA), the Food and Drug Administration (FDA), and the Centers for Medicare and Medicaid Services (CMS). Additionally, there are professional organizations such as the American Board of Pain Medicine (ABPM) and the American Society of Regional Anesthesia and Pain Medicine (ASRA) that set standards and guidelines for pain management professionals.

Key Target Audience
Producer of Pain Management Devices and Drugs, Suppliers of Pain Management Devices and Drugs, Wholesalers, Distributors, and Retailers of Devices and Drugs, Healthcare Industry, Governmental Bodies and Research Firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pharmaceuticals
  • Devices
By Application
  • Burn Pain
  • Cancer Pain
  • Dental/Facial Pain
  • Migraine Headache Pain
  • Musculoskeletal Pain
  • Neuropathic Pain
  • Obstetrical Pain
By Drug Class
  • NSAIDS
  • Anticonvulsants
  • Antidepressants
  • Anti-migraine agents
  • Non-narcotic analgesics
  • Opioids

By Mode Of Purchase
  • Over-The-Counter
  • Prescription Based

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Long-Term Pain Management among the Geriatric Population
      • 3.2.2. High Proven Effectiveness of Pain Management Devices for the Treatment of Chronic Pain
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Therapies for Pain Management
    • 3.4. Market Trends
      • 3.4.1. Growing Popularity of Rechargeable Spinal Cord Stimulators
      • 3.4.2. Development of New Pain Management Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pain Management, by Type, Application, Drug Class, Mode Of Purchase and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Pain Management (Value)
      • 5.2.1. Global Pain Management by: Type (Value)
        • 5.2.1.1. Pharmaceuticals
        • 5.2.1.2. Devices
      • 5.2.2. Global Pain Management by: Application (Value)
        • 5.2.2.1. Burn Pain
        • 5.2.2.2. Cancer Pain
        • 5.2.2.3. Dental/Facial Pain
        • 5.2.2.4. Migraine Headache Pain
        • 5.2.2.5. Musculoskeletal Pain
        • 5.2.2.6. Neuropathic Pain
        • 5.2.2.7. Obstetrical Pain
      • 5.2.3. Global Pain Management by: Drug Class (Value)
        • 5.2.3.1. NSAIDS
        • 5.2.3.2. Anticonvulsants
        • 5.2.3.3. Antidepressants
        • 5.2.3.4. Anti-migraine agents
        • 5.2.3.5. Non-narcotic analgesics
        • 5.2.3.6. Opioids
      • 5.2.4. Global Pain Management by: Mode Of Purchase (Value)
        • 5.2.4.1. Over-The-Counter
        • 5.2.4.2. Prescription Based
      • 5.2.5. Global Pain Management Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Pain Management: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG(Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boston Scientific Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Becton, Dickinson and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medtronic PLC (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson Services, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pain Management Sale, by Type, Application, Drug Class, Mode Of Purchase and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Pain Management (Value)
      • 7.2.1. Global Pain Management by: Type (Value)
        • 7.2.1.1. Pharmaceuticals
        • 7.2.1.2. Devices
      • 7.2.2. Global Pain Management by: Application (Value)
        • 7.2.2.1. Burn Pain
        • 7.2.2.2. Cancer Pain
        • 7.2.2.3. Dental/Facial Pain
        • 7.2.2.4. Migraine Headache Pain
        • 7.2.2.5. Musculoskeletal Pain
        • 7.2.2.6. Neuropathic Pain
        • 7.2.2.7. Obstetrical Pain
      • 7.2.3. Global Pain Management by: Drug Class (Value)
        • 7.2.3.1. NSAIDS
        • 7.2.3.2. Anticonvulsants
        • 7.2.3.3. Antidepressants
        • 7.2.3.4. Anti-migraine agents
        • 7.2.3.5. Non-narcotic analgesics
        • 7.2.3.6. Opioids
      • 7.2.4. Global Pain Management by: Mode Of Purchase (Value)
        • 7.2.4.1. Over-The-Counter
        • 7.2.4.2. Prescription Based
      • 7.2.5. Global Pain Management Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pain Management: by Type(USD Million)
  • Table 2. Pain Management Pharmaceuticals , by Region USD Million (2017-2022)
  • Table 3. Pain Management Devices , by Region USD Million (2017-2022)
  • Table 4. Pain Management: by Application(USD Million)
  • Table 5. Pain Management Burn Pain , by Region USD Million (2017-2022)
  • Table 6. Pain Management Cancer Pain , by Region USD Million (2017-2022)
  • Table 7. Pain Management Dental/Facial Pain , by Region USD Million (2017-2022)
  • Table 8. Pain Management Migraine Headache Pain , by Region USD Million (2017-2022)
  • Table 9. Pain Management Musculoskeletal Pain , by Region USD Million (2017-2022)
  • Table 10. Pain Management Neuropathic Pain , by Region USD Million (2017-2022)
  • Table 11. Pain Management Obstetrical Pain , by Region USD Million (2017-2022)
  • Table 12. Pain Management: by Drug Class(USD Million)
  • Table 13. Pain Management NSAIDS , by Region USD Million (2017-2022)
  • Table 14. Pain Management Anticonvulsants , by Region USD Million (2017-2022)
  • Table 15. Pain Management Antidepressants , by Region USD Million (2017-2022)
  • Table 16. Pain Management Anti-migraine agents , by Region USD Million (2017-2022)
  • Table 17. Pain Management Non-narcotic analgesics , by Region USD Million (2017-2022)
  • Table 18. Pain Management Opioids , by Region USD Million (2017-2022)
  • Table 19. Pain Management: by Mode Of Purchase(USD Million)
  • Table 20. Pain Management Over-The-Counter , by Region USD Million (2017-2022)
  • Table 21. Pain Management Prescription Based , by Region USD Million (2017-2022)
  • Table 22. South America Pain Management, by Country USD Million (2017-2022)
  • Table 23. South America Pain Management, by Type USD Million (2017-2022)
  • Table 24. South America Pain Management, by Application USD Million (2017-2022)
  • Table 25. South America Pain Management, by Drug Class USD Million (2017-2022)
  • Table 26. South America Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 27. Brazil Pain Management, by Type USD Million (2017-2022)
  • Table 28. Brazil Pain Management, by Application USD Million (2017-2022)
  • Table 29. Brazil Pain Management, by Drug Class USD Million (2017-2022)
  • Table 30. Brazil Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 31. Argentina Pain Management, by Type USD Million (2017-2022)
  • Table 32. Argentina Pain Management, by Application USD Million (2017-2022)
  • Table 33. Argentina Pain Management, by Drug Class USD Million (2017-2022)
  • Table 34. Argentina Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 35. Rest of South America Pain Management, by Type USD Million (2017-2022)
  • Table 36. Rest of South America Pain Management, by Application USD Million (2017-2022)
  • Table 37. Rest of South America Pain Management, by Drug Class USD Million (2017-2022)
  • Table 38. Rest of South America Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 39. Asia Pacific Pain Management, by Country USD Million (2017-2022)
  • Table 40. Asia Pacific Pain Management, by Type USD Million (2017-2022)
  • Table 41. Asia Pacific Pain Management, by Application USD Million (2017-2022)
  • Table 42. Asia Pacific Pain Management, by Drug Class USD Million (2017-2022)
  • Table 43. Asia Pacific Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 44. China Pain Management, by Type USD Million (2017-2022)
  • Table 45. China Pain Management, by Application USD Million (2017-2022)
  • Table 46. China Pain Management, by Drug Class USD Million (2017-2022)
  • Table 47. China Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 48. Japan Pain Management, by Type USD Million (2017-2022)
  • Table 49. Japan Pain Management, by Application USD Million (2017-2022)
  • Table 50. Japan Pain Management, by Drug Class USD Million (2017-2022)
  • Table 51. Japan Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 52. India Pain Management, by Type USD Million (2017-2022)
  • Table 53. India Pain Management, by Application USD Million (2017-2022)
  • Table 54. India Pain Management, by Drug Class USD Million (2017-2022)
  • Table 55. India Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 56. South Korea Pain Management, by Type USD Million (2017-2022)
  • Table 57. South Korea Pain Management, by Application USD Million (2017-2022)
  • Table 58. South Korea Pain Management, by Drug Class USD Million (2017-2022)
  • Table 59. South Korea Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 60. Taiwan Pain Management, by Type USD Million (2017-2022)
  • Table 61. Taiwan Pain Management, by Application USD Million (2017-2022)
  • Table 62. Taiwan Pain Management, by Drug Class USD Million (2017-2022)
  • Table 63. Taiwan Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 64. Australia Pain Management, by Type USD Million (2017-2022)
  • Table 65. Australia Pain Management, by Application USD Million (2017-2022)
  • Table 66. Australia Pain Management, by Drug Class USD Million (2017-2022)
  • Table 67. Australia Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Pain Management, by Type USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Pain Management, by Application USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Pain Management, by Drug Class USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 72. Europe Pain Management, by Country USD Million (2017-2022)
  • Table 73. Europe Pain Management, by Type USD Million (2017-2022)
  • Table 74. Europe Pain Management, by Application USD Million (2017-2022)
  • Table 75. Europe Pain Management, by Drug Class USD Million (2017-2022)
  • Table 76. Europe Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 77. Germany Pain Management, by Type USD Million (2017-2022)
  • Table 78. Germany Pain Management, by Application USD Million (2017-2022)
  • Table 79. Germany Pain Management, by Drug Class USD Million (2017-2022)
  • Table 80. Germany Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 81. France Pain Management, by Type USD Million (2017-2022)
  • Table 82. France Pain Management, by Application USD Million (2017-2022)
  • Table 83. France Pain Management, by Drug Class USD Million (2017-2022)
  • Table 84. France Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 85. Italy Pain Management, by Type USD Million (2017-2022)
  • Table 86. Italy Pain Management, by Application USD Million (2017-2022)
  • Table 87. Italy Pain Management, by Drug Class USD Million (2017-2022)
  • Table 88. Italy Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 89. United Kingdom Pain Management, by Type USD Million (2017-2022)
  • Table 90. United Kingdom Pain Management, by Application USD Million (2017-2022)
  • Table 91. United Kingdom Pain Management, by Drug Class USD Million (2017-2022)
  • Table 92. United Kingdom Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 93. Netherlands Pain Management, by Type USD Million (2017-2022)
  • Table 94. Netherlands Pain Management, by Application USD Million (2017-2022)
  • Table 95. Netherlands Pain Management, by Drug Class USD Million (2017-2022)
  • Table 96. Netherlands Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 97. Rest of Europe Pain Management, by Type USD Million (2017-2022)
  • Table 98. Rest of Europe Pain Management, by Application USD Million (2017-2022)
  • Table 99. Rest of Europe Pain Management, by Drug Class USD Million (2017-2022)
  • Table 100. Rest of Europe Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 101. MEA Pain Management, by Country USD Million (2017-2022)
  • Table 102. MEA Pain Management, by Type USD Million (2017-2022)
  • Table 103. MEA Pain Management, by Application USD Million (2017-2022)
  • Table 104. MEA Pain Management, by Drug Class USD Million (2017-2022)
  • Table 105. MEA Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 106. Middle East Pain Management, by Type USD Million (2017-2022)
  • Table 107. Middle East Pain Management, by Application USD Million (2017-2022)
  • Table 108. Middle East Pain Management, by Drug Class USD Million (2017-2022)
  • Table 109. Middle East Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 110. Africa Pain Management, by Type USD Million (2017-2022)
  • Table 111. Africa Pain Management, by Application USD Million (2017-2022)
  • Table 112. Africa Pain Management, by Drug Class USD Million (2017-2022)
  • Table 113. Africa Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 114. North America Pain Management, by Country USD Million (2017-2022)
  • Table 115. North America Pain Management, by Type USD Million (2017-2022)
  • Table 116. North America Pain Management, by Application USD Million (2017-2022)
  • Table 117. North America Pain Management, by Drug Class USD Million (2017-2022)
  • Table 118. North America Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 119. United States Pain Management, by Type USD Million (2017-2022)
  • Table 120. United States Pain Management, by Application USD Million (2017-2022)
  • Table 121. United States Pain Management, by Drug Class USD Million (2017-2022)
  • Table 122. United States Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 123. Canada Pain Management, by Type USD Million (2017-2022)
  • Table 124. Canada Pain Management, by Application USD Million (2017-2022)
  • Table 125. Canada Pain Management, by Drug Class USD Million (2017-2022)
  • Table 126. Canada Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 127. Mexico Pain Management, by Type USD Million (2017-2022)
  • Table 128. Mexico Pain Management, by Application USD Million (2017-2022)
  • Table 129. Mexico Pain Management, by Drug Class USD Million (2017-2022)
  • Table 130. Mexico Pain Management, by Mode Of Purchase USD Million (2017-2022)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Pain Management: by Type(USD Million)
  • Table 142. Pain Management Pharmaceuticals , by Region USD Million (2023-2028)
  • Table 143. Pain Management Devices , by Region USD Million (2023-2028)
  • Table 144. Pain Management: by Application(USD Million)
  • Table 145. Pain Management Burn Pain , by Region USD Million (2023-2028)
  • Table 146. Pain Management Cancer Pain , by Region USD Million (2023-2028)
  • Table 147. Pain Management Dental/Facial Pain , by Region USD Million (2023-2028)
  • Table 148. Pain Management Migraine Headache Pain , by Region USD Million (2023-2028)
  • Table 149. Pain Management Musculoskeletal Pain , by Region USD Million (2023-2028)
  • Table 150. Pain Management Neuropathic Pain , by Region USD Million (2023-2028)
  • Table 151. Pain Management Obstetrical Pain , by Region USD Million (2023-2028)
  • Table 152. Pain Management: by Drug Class(USD Million)
  • Table 153. Pain Management NSAIDS , by Region USD Million (2023-2028)
  • Table 154. Pain Management Anticonvulsants , by Region USD Million (2023-2028)
  • Table 155. Pain Management Antidepressants , by Region USD Million (2023-2028)
  • Table 156. Pain Management Anti-migraine agents , by Region USD Million (2023-2028)
  • Table 157. Pain Management Non-narcotic analgesics , by Region USD Million (2023-2028)
  • Table 158. Pain Management Opioids , by Region USD Million (2023-2028)
  • Table 159. Pain Management: by Mode Of Purchase(USD Million)
  • Table 160. Pain Management Over-The-Counter , by Region USD Million (2023-2028)
  • Table 161. Pain Management Prescription Based , by Region USD Million (2023-2028)
  • Table 162. South America Pain Management, by Country USD Million (2023-2028)
  • Table 163. South America Pain Management, by Type USD Million (2023-2028)
  • Table 164. South America Pain Management, by Application USD Million (2023-2028)
  • Table 165. South America Pain Management, by Drug Class USD Million (2023-2028)
  • Table 166. South America Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 167. Brazil Pain Management, by Type USD Million (2023-2028)
  • Table 168. Brazil Pain Management, by Application USD Million (2023-2028)
  • Table 169. Brazil Pain Management, by Drug Class USD Million (2023-2028)
  • Table 170. Brazil Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 171. Argentina Pain Management, by Type USD Million (2023-2028)
  • Table 172. Argentina Pain Management, by Application USD Million (2023-2028)
  • Table 173. Argentina Pain Management, by Drug Class USD Million (2023-2028)
  • Table 174. Argentina Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 175. Rest of South America Pain Management, by Type USD Million (2023-2028)
  • Table 176. Rest of South America Pain Management, by Application USD Million (2023-2028)
  • Table 177. Rest of South America Pain Management, by Drug Class USD Million (2023-2028)
  • Table 178. Rest of South America Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 179. Asia Pacific Pain Management, by Country USD Million (2023-2028)
  • Table 180. Asia Pacific Pain Management, by Type USD Million (2023-2028)
  • Table 181. Asia Pacific Pain Management, by Application USD Million (2023-2028)
  • Table 182. Asia Pacific Pain Management, by Drug Class USD Million (2023-2028)
  • Table 183. Asia Pacific Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 184. China Pain Management, by Type USD Million (2023-2028)
  • Table 185. China Pain Management, by Application USD Million (2023-2028)
  • Table 186. China Pain Management, by Drug Class USD Million (2023-2028)
  • Table 187. China Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 188. Japan Pain Management, by Type USD Million (2023-2028)
  • Table 189. Japan Pain Management, by Application USD Million (2023-2028)
  • Table 190. Japan Pain Management, by Drug Class USD Million (2023-2028)
  • Table 191. Japan Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 192. India Pain Management, by Type USD Million (2023-2028)
  • Table 193. India Pain Management, by Application USD Million (2023-2028)
  • Table 194. India Pain Management, by Drug Class USD Million (2023-2028)
  • Table 195. India Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 196. South Korea Pain Management, by Type USD Million (2023-2028)
  • Table 197. South Korea Pain Management, by Application USD Million (2023-2028)
  • Table 198. South Korea Pain Management, by Drug Class USD Million (2023-2028)
  • Table 199. South Korea Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 200. Taiwan Pain Management, by Type USD Million (2023-2028)
  • Table 201. Taiwan Pain Management, by Application USD Million (2023-2028)
  • Table 202. Taiwan Pain Management, by Drug Class USD Million (2023-2028)
  • Table 203. Taiwan Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 204. Australia Pain Management, by Type USD Million (2023-2028)
  • Table 205. Australia Pain Management, by Application USD Million (2023-2028)
  • Table 206. Australia Pain Management, by Drug Class USD Million (2023-2028)
  • Table 207. Australia Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Pain Management, by Type USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Pain Management, by Application USD Million (2023-2028)
  • Table 210. Rest of Asia-Pacific Pain Management, by Drug Class USD Million (2023-2028)
  • Table 211. Rest of Asia-Pacific Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 212. Europe Pain Management, by Country USD Million (2023-2028)
  • Table 213. Europe Pain Management, by Type USD Million (2023-2028)
  • Table 214. Europe Pain Management, by Application USD Million (2023-2028)
  • Table 215. Europe Pain Management, by Drug Class USD Million (2023-2028)
  • Table 216. Europe Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 217. Germany Pain Management, by Type USD Million (2023-2028)
  • Table 218. Germany Pain Management, by Application USD Million (2023-2028)
  • Table 219. Germany Pain Management, by Drug Class USD Million (2023-2028)
  • Table 220. Germany Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 221. France Pain Management, by Type USD Million (2023-2028)
  • Table 222. France Pain Management, by Application USD Million (2023-2028)
  • Table 223. France Pain Management, by Drug Class USD Million (2023-2028)
  • Table 224. France Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 225. Italy Pain Management, by Type USD Million (2023-2028)
  • Table 226. Italy Pain Management, by Application USD Million (2023-2028)
  • Table 227. Italy Pain Management, by Drug Class USD Million (2023-2028)
  • Table 228. Italy Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 229. United Kingdom Pain Management, by Type USD Million (2023-2028)
  • Table 230. United Kingdom Pain Management, by Application USD Million (2023-2028)
  • Table 231. United Kingdom Pain Management, by Drug Class USD Million (2023-2028)
  • Table 232. United Kingdom Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 233. Netherlands Pain Management, by Type USD Million (2023-2028)
  • Table 234. Netherlands Pain Management, by Application USD Million (2023-2028)
  • Table 235. Netherlands Pain Management, by Drug Class USD Million (2023-2028)
  • Table 236. Netherlands Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 237. Rest of Europe Pain Management, by Type USD Million (2023-2028)
  • Table 238. Rest of Europe Pain Management, by Application USD Million (2023-2028)
  • Table 239. Rest of Europe Pain Management, by Drug Class USD Million (2023-2028)
  • Table 240. Rest of Europe Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 241. MEA Pain Management, by Country USD Million (2023-2028)
  • Table 242. MEA Pain Management, by Type USD Million (2023-2028)
  • Table 243. MEA Pain Management, by Application USD Million (2023-2028)
  • Table 244. MEA Pain Management, by Drug Class USD Million (2023-2028)
  • Table 245. MEA Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 246. Middle East Pain Management, by Type USD Million (2023-2028)
  • Table 247. Middle East Pain Management, by Application USD Million (2023-2028)
  • Table 248. Middle East Pain Management, by Drug Class USD Million (2023-2028)
  • Table 249. Middle East Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 250. Africa Pain Management, by Type USD Million (2023-2028)
  • Table 251. Africa Pain Management, by Application USD Million (2023-2028)
  • Table 252. Africa Pain Management, by Drug Class USD Million (2023-2028)
  • Table 253. Africa Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 254. North America Pain Management, by Country USD Million (2023-2028)
  • Table 255. North America Pain Management, by Type USD Million (2023-2028)
  • Table 256. North America Pain Management, by Application USD Million (2023-2028)
  • Table 257. North America Pain Management, by Drug Class USD Million (2023-2028)
  • Table 258. North America Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 259. United States Pain Management, by Type USD Million (2023-2028)
  • Table 260. United States Pain Management, by Application USD Million (2023-2028)
  • Table 261. United States Pain Management, by Drug Class USD Million (2023-2028)
  • Table 262. United States Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 263. Canada Pain Management, by Type USD Million (2023-2028)
  • Table 264. Canada Pain Management, by Application USD Million (2023-2028)
  • Table 265. Canada Pain Management, by Drug Class USD Million (2023-2028)
  • Table 266. Canada Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 267. Mexico Pain Management, by Type USD Million (2023-2028)
  • Table 268. Mexico Pain Management, by Application USD Million (2023-2028)
  • Table 269. Mexico Pain Management, by Drug Class USD Million (2023-2028)
  • Table 270. Mexico Pain Management, by Mode Of Purchase USD Million (2023-2028)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pain Management: by Type USD Million (2017-2022)
  • Figure 5. Global Pain Management: by Application USD Million (2017-2022)
  • Figure 6. Global Pain Management: by Drug Class USD Million (2017-2022)
  • Figure 7. Global Pain Management: by Mode Of Purchase USD Million (2017-2022)
  • Figure 8. South America Pain Management Share (%), by Country
  • Figure 9. Asia Pacific Pain Management Share (%), by Country
  • Figure 10. Europe Pain Management Share (%), by Country
  • Figure 11. MEA Pain Management Share (%), by Country
  • Figure 12. North America Pain Management Share (%), by Country
  • Figure 13. Global Pain Management share by Players 2022 (%)
  • Figure 14. Global Pain Management share by Players (Top 3) 2022(%)
  • Figure 15. Global Pain Management share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Novartis AG(Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG(Switzerland) Revenue: by Geography 2022
  • Figure 21. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 25. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Becton, Dickinson and Company (United States) Revenue: by Geography 2022
  • Figure 27. Medtronic PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Medtronic PLC (Ireland) Revenue: by Geography 2022
  • Figure 29. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 34. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 35. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 37. Global Pain Management: by Type USD Million (2023-2028)
  • Figure 38. Global Pain Management: by Application USD Million (2023-2028)
  • Figure 39. Global Pain Management: by Drug Class USD Million (2023-2028)
  • Figure 40. Global Pain Management: by Mode Of Purchase USD Million (2023-2028)
  • Figure 41. South America Pain Management Share (%), by Country
  • Figure 42. Asia Pacific Pain Management Share (%), by Country
  • Figure 43. Europe Pain Management Share (%), by Country
  • Figure 44. MEA Pain Management Share (%), by Country
  • Figure 45. North America Pain Management Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Novartis AG(Switzerland)
  • Merck & Co. Inc. (United States)
  • Boston Scientific Corporation (United States)
  • Becton, Dickinson and Company (United States)
  • Medtronic PLC (Ireland)
  • Johnson & Johnson Services, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Abbott Laboratories (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Additional players considered in the study are as follows:
Mallinckrodt Pharmaceuticals (United Kingdom) , AstraZeneca PLC. (United Kingdom) , Purdue Pharma L.P. (United States) , Depomed, Inc. (United States) , Endo International Plc. (Ireland)
Select User Access Type

Key Highlights of Report


May 2023 200 Pages 88 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Pain Management Quantitative research analysis
Global (United States, European Union and China) Pain Management Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Novartis AG(Switzerland), Merck & Co. Inc. (United States), Boston Scientific Corporation (United States), Becton, Dickinson and Company (United States), Medtronic PLC (Ireland), Johnson & Johnson Services, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Abbott Laboratories (United States) and Teva Pharmaceutical Industries Ltd. (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Popularity of Rechargeable Spinal Cord Stimulators " is seen as one of major influencing trends for Pain Management Market during projected period 2022-2028.
The Pain Management market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) Pain Management Report?

Have a Query? Click Here

Other Related Reports

Laboratory Fume Hood Comprehensive Study by Type (Full Exhaust Fume Hood, Makeup Air Fume Hood, VAV (Variable Air Volume) Fume Hood), Application (Undergraduate Teaching Labs, Industrial and Biomedic...
$ 3350
Ultrasonic Sound Body Composition Comprehensive Study by Type (Dual-Energy X-Ray Absorptiometry (DXA), Air Displacement Plethysmography, Hydrostatic Weighing (HWD), Bio-Impedance Analyzers, Others), ...
$ 3750
Slimming Weight Management Comprehensive Study by Type (Weight Loss Diet, Fitness Equipment, Surgical and Equipment, Weight Loss Programs), Application (Fitness Centers, Gyms, Health Clubs, Others), ...
$ 3450
Adiponectin Testing Comprehensive Study by Type (ELISA Testing, Enzyme Immunoassay Testing, Others), Application (Hospital, Specialty Clinic, Diagnostics Laboratory, Others), Disease Type (Non-Alcoho...
$ 3750
Digital Therapeutics and Wellness Comprehensive Study by Type (Device, Software), Application (Cardiovascular Disease & Hypertension, Diabetes & Prediabetes, Obesity & Weight Loss, Smoking Cessation,...
$ 3450
Veterinary Telemedicine Platform Comprehensive Study by Type (Real-time Chat, Radiology Consulting, Others), Application (Livestock Animals {Poultry, Swine, Cattle, Fish}, Companion Animals {Dogs, Ca...
$ 3750